ArticleJournal of thrombosis and thrombolysis2026
Measurement of plasma direct oral anticoagulants concentrations in real-world clinical and laboratory settings on a 24/7 basis: a 10-year experience.
Article in Journal of thrombosis and thrombolysis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Routine direct oral anticoagulant (DOAC) measurements are not recommended; however, they may be useful in some clinical situations. We sought to evaluate the everyday practice in DOAC measurements on a 24/7 basis including the number of tests over 10 years, indications in out- and inpatients, and turnaround time (TAT) in our tertiary center. From 2013 to 2023, we evaluated all consecutive 758 DOAC measurements performed in 628 patients, aged 61.9 ± 17.6 years mostly with venous thromboembolism (n = 211, 33.5%) and atrial fibrillation (n = 207, 33%) using chromogenic methods. The median number of tests was 6 per month (interquartile range (IQR) 3–9). There were parabolic trend lines for rivaroxaban (n = 308, 40.6%) and dabigatran (n = 241, 32.1%) measurements with a peak in 2017, while apixaban (n = 209, 27.3%) measurements were stable over the study period. The most common indications for DOAC measurements were drug-drug interactions (n = 92, 24.2%) and questionable adherence (n = 60, 15.9%) for outpatients (n = 380, 50.1%), while the assessment of residual DOAC concentrations before invasive procedures (n = 98, 28%) and in embolic stroke of undetermined source (n = 74, 19.6%) were for inpatients (n = 378, 49.9%) including 91 (12%) urgent samples. The median TAT was 89 min (63–126 min) and was shorter by 30 min at the night shifts (n = 256, 33.8%). For emergencies in 2023, TAT reached 42 min (34–54 min). To our knowledge, this is the longest study on how often, in whom, and for which reason DOAC measurements were requested over the last 10 years if a 24/7 service is available. We showed that DOAC measurements are stably requested in inpatients and outpatients but obtaining the results within 30 min is hardly feasible.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.